FDA — authorised 28 May 2020
- Marketing authorisation holder: AVID RADIOPHARMS INC
- Status: approved
🇺🇸 Tauvid in United States
FDA authorised Tauvid on 28 May 2020
Marketing authorisations
FDA — authorised 28 May 2020
- Application: NDA212123
- Marketing authorisation holder: AVID RADIOPHARMS INC
- Local brand name: TAUVID
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
The FDA approved Tauvid, a radioactive diagnostic agent, for labeling on February 5, 2024. Tauvid is manufactured by AVID RADIOPHARMS INC. The approval was granted through the standard expedited pathway. Tauvid is intended for use in patients with Alzheimer's disease.
Tauvid in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in United States
Frequently asked questions
Is Tauvid approved in United States?
Yes. FDA authorised it on 28 May 2020; FDA authorised it on 28 May 2020.
Who is the marketing authorisation holder for Tauvid in United States?
AVID RADIOPHARMS INC holds the US marketing authorisation.